• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
CHM

CHIMERIC THERAPEUTICS LIMITED - News & Media

0.00% ! 0.4¢
Market Cap $8.060M  !
Healthcare Biotechnology
Add to My Watchlist

Chimeric Therapeutics Limited is an Australia-based clinical-stage cell therapy company.... Chimeric Therapeutics Limited is an Australia-based clinical-stage cell therapy company. The Company is focused on the discovery, development, and commercialization of cell therapies for patients with cancer. Its pipeline includes CHM 1101 and CHM 2101. Its CHM 1101 (CLTX CAR-T) is a CAR-T therapy developed for the treatment of patients with solid tumors. CHM-1101 is being studied in a Phase 1B clinical trial in recurrent/ progressive glioblastoma. CHM 2101 is a third generation CDH17 CAR T, which is in preclinical development with a planned Phase I clinical trial in neuroendocrine tumors, colorectal, pancreatic and gastric cancer. Its pipeline also includes the CORE-NK platform, a clinically validated, off-the-shelf natural killer (NK) cell therapy platform to their portfolio (CHM 0201). The Company is also focused on the development of NK and CAR NK assets with plans for Phase 1B clinical trials in solid tumors and blood cancers.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Articles & Videos

Chimeric clocks $4.17M R&D tax rebate from Canberra

Chimeric Therapeutics (ASX:CHM) has confirmed its receipt of a $4.17M tax rebate from Canberra for R&D activities.

28 Nov 2024 11:45 (AEDT)

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Chimeric Therapeutics (ASX:CHM) has reported one leukaemia patient has shown a complete response in its latest drug trial.

07 Oct 2024 11:17 (AEDT)

Chimeric Therapeutics treats first patient in Advent-AML phase 1B clinical trial

Chimeric Therapeutics (ASX:CHM) has treated the first patient in its Advent-AML phase 1B clinical trial at The University of Texas MD Anderson Cancer Center.

08 Feb 2024 13:19 (AEDT)

Chimeric Therapeutics announces positive preclinical data for CHM 1301

Chimeric Therapeutics (ASX:CHM) has announced positive in vitro data for CHM 1301, the company's next-generation CLTX CAR NK cell therapy program.

23 Nov 2023 12:53 (AEDT)

Chimeric Therapeutics to raise $10m through entitlement offer

Chimeric Therapeutics (ASX:CHM) has announced it will conduct an equity raising through a two-for-three entitlement offer of new shares, with the goal of raising up to $10 million.

25 Oct 2023 13:11 (AEDT)

Chimeric Therapeutics (ASX:CHM) completes dose escalation in phase 1A brain cancer trial

Chimeric Therapeutics (ASX:CHM) has treated the third patient participating in its phase 1A dose escalation study at the City of Hope Hospital in California.

29 Aug 2023 14:54 (AEST)



Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Add to My Watchlist
(20min delay)
Last
0.4¢ 		Change
0.000(0.00%) 		Mkt cap ! $8.060M
Open High Low Value Volume
0.5¢ 0.5¢ 0.4¢ $15.69K 3.919M

Buyers (Bids)

No. Vol. Price($)
26 21936206 0.4¢
 

Sellers (Offers)

Price($) Vol. No.
0.5¢ 24685267 27
View Market Depth
Last trade - 16.10pm 13/06/2025 (20 minute delay) ?
CHM (ASX) Chart

Top Stories

Iberian expansion: Megado turns to Europe with Spanish copper mines

Megado Minerals has added the Iberian Copper Project in Spain to its expanding collection after buying an 80% interest in Iberian Copper.
ASX Ltd notches upward on sale of company meant to fix CHESS 3 years ago ASX Ltd (ASX:ASX) has notched fractional gains in early Friday trades on the news it's ditched its shareholdings in...
Zip's stunning comeback: Is this the start of a $14 revival? Just when the market had written it off… Zip Co (ASX: ZIP) has come roaring back to life. The Buy Now, Pay Later company stunned investors last Wednesday with a 15% surge in its share price soon after upgrading its full-year earnings forecast to at least $160 million @ up from $153 million...
Week 24 Wrap: WW3 looms (again); US econ data tepid & silver surfing By and large, I don't think I'd be without peers when I said the biggest thing that happened this week was on energy markets.
Clinuvel shares dip, even as CEO comes back from temp leave After Clinuvel's (ASX:CUV) CEO Dr. Philippe Wolgen took time off back in March to respond to an "acute medical condition," it wasn't...
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.